Enabling the Shift: Innovations in Primary Packaging for Large-Volume Subcutaneous Injections

As the pharmaceutical landscape evolves, the demand for large-volume subcutaneous (LVSC) injections is rapidly growing; driven by the need for home-based treatments, improved patient comfort, and a shift from intravenous (IV) to subcutaneous (SC) delivery. Longer injection times are now clinically accepted, supported by advances in formulation technologies such as hyaluronidase. To meet the rising demand for volumes beyond 2.25 mL, primary packaging must evolve to ensure container integrity, device compatibility, and regulatory readiness. This presentation highlights innovations in large-volume container formats – developed specifically for LVSC use in autoinjectors. Delivered as ready-to-use (RTU) solutions and co-developed with leading device manufacturers, these novel formats are designed to accelerate time to market and reduce implementation risks for pharma partners. By combining proven materials with modern formats and platform compatibility, we enable the next generation of SC biologics to reach patients efficiently and safely.